OCSAW Oculis Holding AG Warrants
$2.39▲ +0.00%
Healthcare
Other
Volume 7.0K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
2.37 - 2.39
% vs 50 MA
-64.32%
% vs 200 MA
–%
RSI-14
38.9
MACD Histogram
+0.3000
Beta (1Y vs SPY)
-1.16
Free Cash Flow
-$20.25M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$22.80M
COGS
–
Operating Exp
$23.57M
Operating Income
-$23.57M
EBIT
-$23.57M
Pretax Income
-$9.96M
Net Income
-$9.97M
Price & Volume History
Loading chart…
Recent News
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
GlobeNewswire · Oct 22, 2026 2:00 AM ET
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
GlobeNewswire · Oct 22, 2026 2:00 AM ET
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
GlobeNewswire · Oct 20, 2026 2:00 AM ET
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
GlobeNewswire · Oct 20, 2026 2:00 AM ET
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
GlobeNewswire · Oct 19, 2026 2:00 AM ET
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
GlobeNewswire · Oct 19, 2026 2:00 AM ET
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
GlobeNewswire · Oct 8, 2026 4:05 PM ET
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
GlobeNewswire · Oct 7, 2026 2:00 AM ET
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
GlobeNewswire · Oct 7, 2026 1:59 AM ET
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
GlobeNewswire · Oct 1, 2026 2:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See OCSAW's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.